Hipozinquemia en pacientes mexicanos con úlcera de pie diabético tratados en el primer nivel de atención

Abstract

Objective: To know the frequency of people with hypozincemia in a group of Mexican patients with Diabetic Foot Ulcers (DFU) m and its relationship with metabolic and clinical profile. Material and methods: Cross-sectional, analytical, and observational study in patients with and without DFU, treated in Family Medicine Units from Instituto Mexicano del Seguro Social (IMSS) in Mérida, Yucatán, México. Frequency of hypozincemia (Zn serum < 70 g/ml) and its relationship with the levels of Glycosylated Hemoglobin (HbA1c), cholesterol and triglycerides was analyzed. Results: 70% of patients with DFU and 25% without DFU had hypozincemia (OR = 5.2, 95% CI 2.139-12.65, p = 0.0004). Patients with hypozincemia were older and the highest prevalence was between 50 and 60 years. The average area of the DFU showed no differences in patients with and without hypozincemia. Patients with DFU reported higher levels of HbA1c, cholesterol, triglycerides, BMI, and blood pressure compared to patients without DFU. Hypozincemia was associated with higher BMI values. Conclusion: The frequency of hypozincemia in diabetic patients with UPD is high and is behaving as a risk factor for presenting UPD, so its identification should be routine.

A review on contemporary nanomaterial-based therapeutics for the treatment of diabetic foot ulcers (DFUs) with special reference to the Indian scenario

“…Approximately 15–30% of diabetic individuals attain DFUs, leading to substantial wound management throughout their life. 37,38 The incidence of diabetes accounts for 8 out of 10 nontraumatic-type amputations. The percentage mortality ranges from 15–42% in 2 years, 34–64% in 4 years and 40–80% in 6 years.…”